Faculty Bibliography

BACKGROUND:Studies of type 1 diabetes in sub-Saharan Africa have suggested that the clinical phenotype might differ from phenotypes reported elsewhere. We aimed to establish whether type 1 diabetes diagnosed in children and young adults in three countries across sub-Saharan Africa is of autoimmune origin. METHODS:In this observational, cross-sectional study, we identified participants without obesity from outpatient clinics in government and private hospitals in Cameroon, Uganda, and South Africa who were of self-reported Black African ethnicity with young-onset (age <30 years), insulin-treated, clinically diagnosed type 1 diabetes. We measured islet autoantibodies to GADA, IA-2A, and ZnT8A, and calculated a genetic risk score (GRS) for type 1 diabetes, which we compared with control populations without diabetes derived from the Uganda Genome Resource databank and other studies. Endogenous insulin secretion was assessed using plasma C-peptide. We compared findings with those for participants with self-reported Black (n=429) and White (n=2602) ancestry with type 1 diabetes from the SEARCH for Diabetes in Youth (SEARCH) study in the USA. FINDINGS/RESULTS:(19·5-24·1). Only 312 (34·9%) of 894 participants were positive for islet autoantibodies; these participants had classic features of type 1 diabetes, including 225 (82·7%) of 272 with plasma C-peptide <200 pmol/L, and high type 1 diabetes GRS. Those without islet autoantibodies (582 [65·1%] of 894) had significantly lower median type 1 diabetes GRS than those with autoantibodies (9·66 [IQR 7·77-11·33] vs 11·76 [10·49-12·91]; p<0·0001), suggesting a subgroup with a non-autoimmune diabetes subtype, with clinical features and C-peptide concentrations not consistent with type 2 diabetes. Among participants diagnosed younger than 20 years, autoantibody-negative diabetes was also observed in 65 (15·1%) of 429 participants with Black ancestry in SEARCH (although less frequently than in sub-Saharan Africa [59 (55·1%) of 107]), and these participants also had a low type 1 diabetes GRS (median 10·41 [IQR 8·65-12·22] in autoantibody-negative subgroup). No such pattern was observed in White participants in SEARCH: 241 (9·3%) of 2602 were autoantibody negative and median GRS for type 1 diabetes was similar in autoantibody-negative and autoantibody-positive participants (median 13·42 [IQR 11·80-14·61] vs 13·49 [12·29-14·58]). INTERPRETATION/CONCLUSIONS:In sub-Saharan Africa, clinically diagnosed type 1 diabetes is heterogeneous, comprising classic autoimmune type 1 diabetes and a novel, non-autoimmune, insulin-deficient diabetes subtype. There is evidence of this subtype in Black but not White individuals in the USA. Therefore, alternative causes must be considered in this group of individuals, and understanding the drivers of this subtype might offer new insights into prevention and treatment. FUNDING/BACKGROUND:UK National Institute of Health and Care Research. TRANSLATION/UNASSIGNED:For the French translation of the abstract see Supplementary Materials section.

IMPORTANCE:Artificial intelligence (AI)-assisted ambient documentation technologies that use audio from clinic visits to generate documentation are being deployed across hospital systems to optimize clinical note writing and reduce administrative burden. However, little is known about optimal approaches to engage patients in informed consent for these tools. OBJECTIVES:To explore clinician and patient experiences with consent processes and examine the association between the use of ambient documentation tools and the patient-clinician relationship. DESIGN, SETTING, AND PARTICIPANTS:This study was conducted from March 1 to December 31, 2024, in ambulatory practices across specialties in a large urban academic health center as part of an ongoing operational quality improvement initiative. Participants included clinicians and patients participating in an operational proof-of-concept exploration of ambient documentation technology. MAIN OUTCOMES AND MEASURES:A pragmatic, sequential, inductive-deductive qualitative evaluation was conducted of informed consent contexts, processes, and challenges among ambulatory clinicians and patients exposed to ambient documentation technology. Evaluation included site visits, clinical observations, clinician interviews, and patient surveys to explore perceptions and challenges related to consent. RESULTS:A total of 121 ambient documentation pilot users included 18 clinicians (mean [SD] years of practice, 18.6 [100]; 10 men [55.6%]) and 103 patients (mean [SD] age, 37 [12.5] years; 65 women [63.1%]). The most common consent approach was a verbal patient-clinician conversation prior to an individual encounter. Patients and clinicians had a spectrum of comfort with ambient technology; 77 patients (74.8%) reported being comfortable or very comfortable with their physician using ambient documentation. Patient trust, detail in the consent discussion, and intended tool use were associated with patient comfort and intent to consent. Technical understanding was associated with comfort with consent conversations: when provided basic information about the technology, 84 patients (81.6%) consented; this decreased to 57 patients (55.3%) when details about AI features, data storage, and corporate involvement were disclosed. Perceived benefits included reduced documentation burden, improved decision-making, and enhanced communication. Concerns included data security, legal liability, cognitive impacts, and equity. When asked about responsibility for medical errors linked to ambient documentation, 66 patients (64.1%) held physicians accountable; for data security breaches, 79 patients (76.7%) believed vendors should be responsible. Participants suggested a flexible consent model with digital touchpoints, education, nonclinical staff support, and opt-out options. CONCLUSIONS AND RELEVANCE:In this quality improvement study of 121 pilot users of AI-assisted ambient documentation technology, informed consent relied primarily on verbal conversations that varied based on time, knowledge, and the patient-clinician relationship. A flexible, multimodal approach-including education, time to discuss risks and benefits, digital resources, nonclinical staff involvement, and clear opt-out options-may improve consent processes and support broader acceptance of ambient documentation tools.

Colorectal cancer (CRC) screening uptake in the Veterans Health Administration (VA) has been reported to be higher than the US general population, but CRC remains a prevalent cancer within the VA system. To examine CRC predictors and the extent to which the conventional definition of up-to-date screening applies to the population, we conducted a case-control study using VA data from 2012 to 2018. We classified patients into 5 categories: up-to-date or not up-to-date average-risk patients aged 50 to 75 (Categories 1 and 2), up-to-date or not up-to-date average-risk patients aged <50 or >75 (Categories 3 and 4), and high-risk patients (Category 5). Each CRC case was matched by age, sex, and facility with 4 controls. We performed multivariable conditional logistic regression, adjusting for race and ethnicity, diabetes, obesity, and alcohol use. Among 3714 CRC cases identified, Category 4 (odds ratio [OR] 1.40, 95% CI 1.11-1.78) and Category 5 (OR 6.23, 95% CI 5.06-7.66) patients had a higher risk of CRC compared to Category 1 patients. Compared with White patients, Black patients had a higher risk (OR 1.54, 95% CI 1.37-1.73). Diabetes (OR 1.65, 95% CI 1.51-1.81) and alcohol use disorder (OR 1.53, 95% CI 1.35-1.73) were also associated with CRC. Most CRC cases occurred in individuals aged 50 to 75, but 12.5% occurred in persons who were outside of this age range or had high-risk personal or family history. The conventional measure of CRC screening, focused on average-risk individuals aged 50 to 75, does not reflect screening status in an important minority of CRC patients.

The COVID-19 pandemic catalyzed a rapid expansion of telemedicine across the United States, expanding access to video-based services but also raising concerns about equitable access, use, and experience among minority populations. This mixed-methods scoping review quantitatively describes patterns of video-based telemedicine utilization and qualitatively evaluates factors impacting utilization among racial/ethnic minorities in the United States during the COVID-19 pandemic. We conducted a comprehensive literature search across six databases for studies published between January 2020 and March 2023. Eligible studies reported on telehealth or telemedicine use, specifically video-based visit utilization among racial/ethnic minorities. Reviewers independently screened studies, extracted data, and synthesized findings using an integrated mixed-methods approach. Of 1801 studies, 77 studies met the inclusion criteria. Of these, a majority were published in metropolitan coastal areas, and most were heterogeneous in their definition of telemedicine and utilization. Quantitatively, 33 studies (42.9%) reported increased use of video-based telemedicine, 29 (37.7%) reported decreased use, and 15 (20%) reported variable use across racial/ethnic subgroups. Most studies assessed disparities among non-Hispanic Black and Hispanic/Latinx populations (73 and 66 studies, respectively), while fewer examined disparities among other minority populations (45 studies). Factors associated with telemedicine adoption included patient- and community-level digital access barriers, low organizational digital capacity and infrastructure, implicit bias, and inadequate provider education and training. Identified facilitators included trust and awareness of telemedicine, adequate provider training, cultural and linguistic adaptations, targeted internet subsidies, and telemedicine reimbursements. Video-based telemedicine utilization among racial/ethnic minorities during the COVID-19 pandemic was heterogeneous, influenced by individual, systemic, and implementation factors. Disparities were most pronounced among Asians and other minority populations. Despite increased attention and efforts to address access barriers, our findings highlight the need for more targeted, culturally and structurally tailored interventions to improve digital inclusion.

RATIONALE/BACKGROUND:Abrupt air quality improvements have followed the closure or dramatic emission control of large air pollution sources. These "natural experiments" provide ideal opportunities to assess the real-world health benefits of air quality improvements. The shutdown of the Shenango coking plant, a significant fossil-fuel pollution source located on an island in the Ohio River near Pittsburgh, PA, presented such an opportunity to test for changes in respiratory health in the local community following the closure. OBJECTIVES/OBJECTIVE:To identify and quantify the immediate and/or longer-term changes in respiratory hospitalizations and emergency department (ED) visits among the population residing near the Shenango coke plant at the time of its closure. METHODS:We acquired data for respiratory hospitalizations and ED visit counts by residents living in zip codes surrounding the plant, as well as at comparison control sites, three years before and after the shutdown date. The immediate and longer-term changes of respiratory health outcomes were tested with an interrupted time series model, and compared with external control sites and internal control outcomes. MEASUREMENTS AND MAIN RESULTS/RESULTS:We found the closure of the Shenango plant was associated with an immediate 20.5% (95% CI: 12.8%-27.6%) decrease for weekly respiratory ED visits, and an immediate 41.2% (95% CI: 14.4%-59.9%) decrease in pediatric asthma ED visits, followed by an additional 4% per month longer-term downward trend. Longer-term reductions, as compared to pre-closure trends, were also observed for chronic obstructive pulmonary disease hospitalizations. CONCLUSIONS:Our study provides strong confirmation that reductions in fossil-fuel-related air pollution produce both short and longer-term respiratory health benefits. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Prenatal exposure to benzotriazoles and benzothiazoles (BTs) has been associated with pregnancy complications, but their effects on childhood development remain unclear. We investigated these associations and examined the mediating role of maternal and neonatal thyroid hormones in a Chinese birth cohort consisting of 501 mother-child pairs. We found that exposure to 2-hydroxy-benzothiazole (2-OH-BTH) in early pregnancy was inversely associated with childhood body mass index (BMI) (β = -0.041, 95% CI: -0.077, -0.005). Both tolyl-triazole (TTR) (β = -1.35%, 95% CI: -2.45%, -0.24%) and 2-OH-BTH (β = -1.15%, 95% CI: -1.79%, -0.50%) were inversely associated with maternal free thyroxine (FT4) in early pregnancy, which mediated 23.53% of the inverse associations between 2-OH-BTH exposure and childhood BMI. Additionally, third-trimester exposure to 1-hydroxy-benzotriazole, xylyl-triazole, TTR, and 2-OH-BTH was positively linked to neonatal thyroid-stimulating hormone levels. These findings suggest that prenatal exposure to BTs, particularly 2-OH-BTH, may impair early childhood growth by disrupting thyroid hormone homeostasis. Our results add new epidemiological evidence to the growing concern about BTs and underscore the importance of considering thyroid disruption as a mechanistic link between environmental exposures and developmental outcomes. This highlights the need for greater public health attention and regulatory measures targeting these emerging contaminants.

BACKGROUND:Use of party drugs is common among nightclub attendees, but more information is needed regarding both intentional use and unknown exposure to synthetic cathinones, fentanyl, and xylazine in this high-risk population. METHODS:Throughout 2024, participants attending nightclubs in New York City were surveyed and had their saliva analyzed for drug exposure using targeted and untargeted analysis (n = 1024). We calculated the prevalence of synthetic cathinone, fentanyl, and xylazine exposure overall and in relation to demographic and drug use characteristics. RESULTS:11 (1.1 %) tested positive for one or more synthetic cathinones, 1.5 % (n = 15) tested positive for fentanyl or its precursor (4-ANPP), and 4 (0.4 %) tested positive for xylazine. All but one exposure to fentanyl was linked to unreported past-month use (93.3 %) and 54.5 % of synthetic cathinone exposures were linked to unreported past-month use (ps<.05). Three of four participants (75.0 %) testing positive for xylazine also tested positive for fentanyl exposure. Most (n = 8) synthetic cathinone exposures involved methylmethcathinone (MMC), and there were also detections of chloromethcathinone (CMC, n = 4), N-N-dimethylpentylone (n = 2), N-ethylpentylone (n = 2), and eutylone (n = 2). Compared to those testing positive for synthetic cathinones, those testing positive for fentanyl were more likely to identify as heterosexual and/or test positive for prescription opioid use, and less likely to have a college degree or to test positive for MDMA use (ps<.05). CONCLUSIONS:Unintentional exposure to these drugs is occurring, often because they have been added as adulterants in more common drugs. Results can inform prevention and harm reduction education in this population and in the general population.

OBJECTIVES/OBJECTIVE:We aimed to describe pediatric firearm incidents treated at 6 New York City public trauma hospitals over a 5-year period. METHODS:We conducted a retrospective, multi-institutional, descriptive study of firearm-related incidents among patients below 18 years treated at 6 municipal trauma centers in New York City from July 1, 2016, to June 30, 2021. We used trauma registries, electronic health records (EHR), and geospatial analysis, supplemented with Gun Violence Archive (GVA) and New York Police Department data to characterize and map incidents, excluding missing data. RESULTS:Of n=176 patients, data on injury intent and circumstances were unavailable for 13% (n=22) and 22% (n=38), respectively. Most were male (n=161, 91%), Black (n=133, 76%), and adolescents (median 16 y, IQR: 15, 17) who sustained nonfatal (n=166, 94%) assaults (n=151, 98%). Limited available data suggests that identified assailants were unknown to the unintentional victims of community violence. Incidents largely occurred on weekdays (n=133, 76%); between 15:00 and 20:59 (n=72, 42%); and outside a residential home (n=149, 93%), including sidewalk/street (n=85, 53%) and playground/park/basketball court (n=25, 16%). The most common circumstances were running/jogging/walking outside (n=54, 39%), altercation involvement (n=32, 23%), and drive-by (n=27, 20%). Fifty-four percent (n=72) of incidents occurred within 0.2 miles of public housing in 3 primary geospatial clusters. GVA and New York Police Department databases suggest between 39% and 46% capture of relevant incidents. CONCLUSIONS:Regional gun violence data suffers from a lack of standardization and missingness across sources. Nonetheless, triangulating available data from trauma registries, EHR, GVA, and geospatial analysis, we found that most pediatric patients were Black, adolescent, unintended victims who sustained assaults on weekdays, outside a home, and within 0.2 miles of public housing in 3 primary clusters. These results may inform hospital data surveillance and ongoing evidence-based prevention strategies.

BACKGROUND:Routine collection and use of sexual orientation and gender identity data can assist in understanding and addressing the health disparities that affect lesbian, gay, bisexual, transgender, queer+ (LGBTQ+), also known as sexual and gender minority, individuals and communities. This study explored the implementation of a culturally relevant sexual and gender minority/sexual orientation and gender identity training program at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. METHODS:The training consisted of 6 in-person 15-minute modules or 3 virtual 30-minute modules that occurred during established high-reliability organization huddles attended by oncology faculty and staff. Module topics were (1) Building LGBTQ+ Knowledge & LGBTQ+ Cancer Disparities, (2) Creating an Inclusive Environment, (3) Recovering From Misgendering/Making Assumptions, (4) How to Receive & Respond to Feedback, (5) Witnessing & Responding to Discrimination, and (6) Making and Sustaining a Change. All high-reliability organization attendees were considered eligible for participation and were provided with pretraining and post-training surveys. Survey items included comfort caring for sexual and gender minority patients, practice collecting sexual orientation and gender identity data, knowledge of sexual and gender minority health, and demographics. RESULTS:A total of 344 individuals completed the presurvey and 187 completed the postsurvey. Postsurvey results demonstrated a statistically significant improvement in self-perceived knowledge about sexual and gender minority health (scale: 0-100, with 100 = highest; presurvey vs postsurvey, 69 vs 84; P < .001). Respondents also reported statistically significant improvements in confidence in engaging with sexual orientation and gender identity questions (53 vs 79, P < .001) as well as intention to collect patient sexual orientation and gender identity information (49 vs 75, P < .001). Notably, sexual orientation and gender identity data collection tracking demonstrated a 311% increase in sexual orientation and 262% in gender identity disclosure during the study period. CONCLUSION/CONCLUSIONS:Despite the availability of sexual orientation and gender identity data fields within electronic health records, sexual orientation and gender identity disclosure remains an ongoing nationwide problem. Use of culturally relevant sexual and gender minority/sexual orientation and gender identity training can help improve oncology staff and clinician sexual and gender minority knowledge and confidence when engaging patients with and subsequent documentation of sexual orientation and gender identity data, resulting in improvement of data completion.

Brain health is pivotal to achieving overall health and all current sustainable development goals (SDGs). However, a dedicated training program in brain health research to unravel its complex determinants, especially genetic, sociodemographic and lifestyle factors is lacking in Africa. The Growing Data-science Research in Africa to Stimulate Progress (GRASP) is a three-year program designed to harness innovation potential to build sustainable data science (DS) research capacity among qualified African scholars through innovative partnerships and collaborations. This is aimed at promoting a learning environment for boosting knowledge, managing expectations, building support systems, and overcoming environmental barriers to create a sustainable system that will inspire innovative thinking for a remarkable transformation for producing Brain Health solutions for African and the world. Highlight of GRASP is its focus on improving the DS skills of selected scholars to explore sociodemographic determinants, dietary and lifestyle factors affecting brain health and cardiovascular risks, integrating sociodemographic data with cognitive, genomics, climate and geographical data. Ten African scholars from a cross-national/multidisciplinary postgraduate clinicians and researchers pool were selected during the 2024 cycle. Activities lined up during this program comprises of a nine-month Postgraduate Certificate program that includes six months virtual training activities, a compulsory 6-week residency at the University of Ibadan (UI), Nigeria (exclusive for five outstanding performing scholars), networking sessions at scientific meetings, annual mentor-mentee communication and research project. GRASP complements these attributes with the Master of Science in Clinical Research (MSCR) degree including competencies for the clinical and translational research workforce. GRASP scholars are assessed with periodic monitoring within three years after program completion based on academic positions and publications; funding for investigator-initiated research projects or career development awards. Building DS research capacity among African scholars via the GRASP program will re-orient current understanding and inspire creative solutions in Africa's approach to combating NCDs.